Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside. / Ashina, Messoud; Hoffmann, Jan; Ashina, Håkan; Hay, Debbie L.; Flores-Montanez, Yadira; Do, Thien Phu; De Icco, Roberto; Dodick, David W.
I: Mayo Clinic Proceedings, Bind 99, Nr. 2, 2024, s. 285-299.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside
AU - Ashina, Messoud
AU - Hoffmann, Jan
AU - Ashina, Håkan
AU - Hay, Debbie L.
AU - Flores-Montanez, Yadira
AU - Do, Thien Phu
AU - De Icco, Roberto
AU - Dodick, David W.
N1 - Publisher Copyright: © 2023 Mayo Foundation for Medical Education and Research
PY - 2024
Y1 - 2024
N2 - Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.
AB - Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.
U2 - 10.1016/j.mayocp.2023.07.003
DO - 10.1016/j.mayocp.2023.07.003
M3 - Review
C2 - 38180396
AN - SCOPUS:85184278621
VL - 99
SP - 285
EP - 299
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 2
ER -
ID: 382978472